Periodontal HealthNCT06255470
Effect of Periodontal Treatment on Salivary and Serum Biomarkers in Periodontitis
A study testing Non-surgical periodontal treatment in people with Periodontal Health and Periodontitis, run by Marmara University at 1 site in Turkey (Türkiye).
Trial summary
The present study aimed to determine the effect of non-surgical periodontal treatment on serum and salivary SIRT-1, MMP-9, and T-SOD levels in periodontitis stage III grade B (P-III-B) and C (P-III-C) patients. 17 periodontally healthy, 16 P-III-B and 16 P-III-C subjects were enrolled. Read more about this study
- Who is it for?
- Ages 23 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontal Health, Periodontitis
- What is being tested?
- Non-surgical periodontal treatment
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 49 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Sep 2022to 1 Nov 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 23 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- systemically healthy and non-smoker individuals
- having ≥20 teeth present (except third molars)
- individuals with periodontally healthy, periodontitis stage III grade B and C diagnoses
Who cannot join
- having any diagnosed medical disorders such as diabetes mellitus, cardiovascular diseases, rheumatoid arthritis, immunological and mucocutaneous diseases
- usage of antibiotics, non-steroidal anti-inflammatory drugs and immunosuppressive agents within the past 6 months
- having any non-inflammatory destructive periodontal disease
- nonsurgical/surgical periodontal therapy received in the past year
- pregnant/ lactating/ postmenopausal females.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Marmara University, Faculty of Dentistry, Department of Periodontology
Istanbul
About this study
Official title: Effect of Periodontal Treatment on Salivary and Serum SIRT-1, MMP-9 and T-SOD Levels
The present study aimed to determine the effect of non-surgical periodontal treatment on serum and salivary SIRT-1, MMP-9, and T-SOD levels in periodontitis stage III grade B (P-III-B) and C (P-III-C) patients. 17 periodontally healthy, 16 P-III-B and 16 P-III-C subjects were enrolled. At baseline, serum and saliva samples were collected and the whole mouth clinical periodontal parameters were recorded. Periodontitis patients received non-surgical periodontal treatment. Clinical parameters were re-measured and samples were re-collected at 3 months after treatment. Serum and salivary SIRT-1, MMP-9, and T-SOD levels were analyzed by ELISA. Data were analyzed using appropriate statistical tests.
Read the detailed description
Periodontitis is a dysbiotic chronic inflammatory disease that compromises the integrity of the tooth-supporting tissues. When periodontitis occurs, reactive oxygen species, which are overproduced mostly by hyperactive neutrophils, can not be balanced by the antioxidant defense system and cause tissue damage. Cytoprotective enzymes such as superoxide dismutase (SOD), catalase (Cat) and the regulatory pathways that influence them, play a critical role in the scavenging and detoxification of ROS. Sirtuin-1 (SIRT-1) is a nicotinamide adenine dinucleotide (NAD)dependent histone deacetylase. SIRT1 is known to deacetylate FOXO3a, which induces antioxidant responses via modulation in SOD2 and CAT. Moreover, SIRT1 overexpression downregulates the pro-inflammatory cytokines such as interleukin (IL)-1α, IL-6, IL-8 and tumor necrosis factor-α (TNF-α) synthesis which are associated with the onset and progression of the periodontal disease. MMP-9 is a host-derived proteolytic enzyme that leads to periodontal tissue breakdown and is activated by oxidative stress.
This study aims to examine the effect of non-surgical periodontal treatment (NSPT) on saliva and serum SIRT-1, SOD and MMP-9. It is the first controlled clinical study investigating the effect of NSPT on salivary SIRT-1 levels in different periodontitis groups. The sample size was calculated based on a previous study investigating the level of salivary MMP-9 and the power of the test was 95%, alfa value: 0.05. The estimated sample size was 10 individuals for each group. Therefore, a total of 49 systemically healthy patients; 17 periodontally healthy, 16 P-III-B, 16 P-III-C were included in this study. Periodontal examination was performed, and full medical and dental histories were collected by a single examiner at baseline and 3 months after NSPT. The whole mouth clinical periodontal examination included measurement of probing depth (PPD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI), and plaque index (PI) at 6 sites per tooth, except the third molars. The presence and type of the alveolar bone loss were assessed on the digital panoramic radiograph in each participant, which was supplemented with periapical radiographs if necessary. Periodontal status of each patient was evaluated by a single calibrated periodontists with a manual probe. The diagnosis of periodontitis or periodontal health was determined according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Periodontally healthy individuals (n=17) in the control group had no sites with PD >3 mm and CAL >2 mm and also no radiographic evidence of alveolar bone loss. BOP was <10%.
The periodontitis stage III patients had a minimum of three teeth apart from the first molars and incisors showing CAL ≥5 mm and PD ≥6 mm and showed no>4 teeth loss because of periodontitis. Radiographic bone loss extending from coronal to middle third or beyond. Radiographic bone loss was determined from the tooth showing the most severe bone loss as a percentage of root length. If the values of bone loss %/age were between 0.25 and 1.0, the patients were assigned to grade B (n=16). If higher than 1.0, the patients were assigned to grade C (n=16).
Treatment
Patients in the periodontitis groups underwent quadrant-wise supra and subgingival mechanical scaling and root planing using ultrasonic scalers and manual instruments, after administration of local anesthesia. No periodontal intervention was carried out in the periodontally healthy controls.
Saliva and Serum Sampling
A total of 5 mL of unstimulated whole saliva was collected by passive drool method between 9:00 and 10:00 am. The participants were advised to avoid food consumption for three hours before sample collection. The participants were seated upright, and saliva was collected over a period of 5 minutes with instructions to pool saliva in the floor of the mouth and passively drool it into a sterile glass beaker. Then saliva samples are immediately transferred to a 2 mL polypropylene tube and stored at -80°C. A total of 5 mL of blood was collected from the antecubital fossa by vene puncture method. Serum was isolated from the blood by centrifuging at 5000 rpm for 10 minutes followed by its rapid transfer to a sterile polypropylene tube and storage at -80°C.
Biomarker Immunoassays Saliva and serum samples were thawed on ice. The saliva samples were centrifuged at 5.000 rpm for 15 minutes at room temperature, and supernatants were immediately used for assays. Serum and salivary samples of SIRT-1 , MMP-9, MIP-1α*, T-SOD were measured by ELISA using commercial kits.
Statistical Analysis
All statistical analyses were carried out with the standard statistical software package. For the intra-group comparisons, if the data were not normally distributed, Wilcoxon-signed rank test and the Dunn test with the Bonferroni correction were used to analyze the change between baseline and 3 months after treatment. For inter-group comparisons, Mann-Whitney U test for normally and non-normally distributed data. The Spearman's rank correlation test was used to detect the correlations of biochemical parameters with clinical parameters and each other's in diseased group before and after treatment. All tests were performed at significance level of P <0.05.
- Conditions
- Periodontal Health, Periodontitis
- Being tested
- Non-surgical periodontal treatment
- Keywords
- periodontitis, periodontal treatment
- Medical subject headings
- Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Non-surgical periodontal treatmentProcedure or surgery
Non-surgical periodontal treatment involves the removal of microbial dental plaque and calculus by mechanical debridement using manual and ultrasonic instruments. Motivating and educating patients about oral hygiene procedures is another important part of the treatment. The aim is to stop the progression of the disease and to prevent the occurrence of active clinical inflammation.
| Study group | Role | What they receive |
|---|---|---|
| Periodontally Healthy | No intervention | Periodontally healthy patients received no intervention. |
| Periodontitis Stage III Grade B | Active comparator | The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia by the use of ultrasonic scalers and curettes. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks. Receives: Procedure: Non-surgical periodontal treatment |
| Periodontitis Stage III Grade C | Active comparator | The patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia by the use of ultrasonic scalers and curettes. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks. Receives: Procedure: Non-surgical periodontal treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Salivary SIRT-1 (ng/mL) level
change in salivary SIRT-1 levels from baseline to 3 months after treatment
Measured: baseline to 3 months after treatment
Salivary MMP-9 (ng/mL) level
change in salivary MMP-9 levels from baseline to 3 months after treatment
Measured: baseline to 3 months after treatment
Salivary T-SOD (U/mL) level
change in salivary T-SOD levels from baseline to 3 months after treatment
Measured: baseline to 3 months after treatment
Secondary outcomes (3)
Serum SIRT-1 (ng/mL) level
change in serum SIRT-1 levels from baseline to 3 months after treatment
Measured: baseline to 3 months after treatment
Serum MMP-9 (ng/mL) level
change in serum MMP-9 levels from baseline to 3 months after treatment
Measured: baseline to 3 months after treatment
Serum T-SOD (U/mL) level
change in serum T-SOD levels from baseline to 3 months after treatment
Measured: baseline to 3 months after treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2024
- Study start1 Sep 2022
- Primary completion1 Nov 2023
- Study completion1 Nov 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Periodontal HealthStudies of the same condition, open and under way.
- More trials run by Marmara UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 49 participants (actual)
Sponsor and investigators
- Lead sponsor
- Marmara University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06255470
- Sponsor's protocol ID
- 09.2022.863
- Status last verified
- Jan 2024
- First submitted
- 4 Feb 2024
- Last updated
- 13 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Iyigun S, Gorgulu NG, Dogan B. Changes in MMP-9, T-SOD and SIRT-1 levels after non-surgical periodontal treatment. BMC Oral Health. 2025 Feb 19;25(1):262. doi: 10.1186/s12903-025-05610-5.
PubMed 39972299
Study at a glance
From the registry record, last updated by the sponsor on 13 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Periodontal Treatment on Salivary and Serum SIRT-1, MMP-9 and T-SOD Levels
- ClinicalTrials.gov ID
- NCT06255470
- Acronym / sponsor ID
- 09.2022.863
- Conditions
- Periodontal Health, Periodontitis
- Keywords
- periodontitis, periodontal treatment
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 49 participants (actual)
- Lead sponsor
- Marmara UniversityUniversity, hospital or other
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 1 Nov 2023 (actual)
- Study completion
- 1 Nov 2023 (actual)
- First posted
- 13 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present study aimed to determine the effect of non-surgical periodontal treatment on serum and salivary SIRT-1, MMP-9, and T-SOD levels in periodontitis stage III grade B (P-III-B) and C (P-III-C) patients. 17 periodontally healthy, 16 P-III-B and 16 P-III-C subjects were enrolled. At baseline, serum and saliva samples were collected and the whole mouth clinical periodontal parameters were recorded. Periodontitis patients received non-surgical periodontal treatment. Clinical parameters were re-measured and samples were re-collected at 3 months after treatment. Serum and salivary SIRT-1, MMP-9, and T-SOD levels were analyzed by ELISA. Data were analyzed using appropriate statistical tests.
Detailed description
Periodontitis is a dysbiotic chronic inflammatory disease that compromises the integrity of the tooth-supporting tissues. When periodontitis occurs, reactive oxygen species, which are overproduced mostly by hyperactive neutrophils, can not be balanced by the antioxidant defense system and cause tissue damage. Cytoprotective enzymes such as superoxide dismutase (SOD), catalase (Cat) and the regulatory pathways that influence them, play a critical role in the scavenging and detoxification of ROS. Sirtuin-1 (SIRT-1) is a nicotinamide adenine dinucleotide (NAD)dependent histone deacetylase. SIRT1 is known to deacetylate FOXO3a, which induces antioxidant responses via modulation in SOD2 and CAT. Moreover, SIRT1 overexpression downregulates the pro-inflammatory cytokines such as interleukin (IL)-1α, IL-6, IL-8 and tumor necrosis factor-α (TNF-α) synthesis which are associated with the onset and progression of the periodontal disease. MMP-9 is a host-derived proteolytic enzyme that leads to periodontal tissue breakdown and is activated by oxidative stress.
This study aims to examine the effect of non-surgical periodontal treatment (NSPT) on saliva and serum SIRT-1, SOD and MMP-9. It is the first controlled clinical study investigating the effect of NSPT on salivary SIRT-1 levels in different periodontitis groups. The sample size was calculated based on a previous study investigating the level of salivary MMP-9 and the power of the test was 95%, alfa value: 0.05. The estimated sample size was 10 individuals for each group. Therefore, a total of 49 systemically healthy patients; 17 periodontally healthy, 16 P-III-B, 16 P-III-C were included in this study. Periodontal examination was performed, and full medical and dental histories were collected by a single examiner at baseline and 3 months after NSPT. The whole mouth clinical periodontal examination included measurement of probing depth (PPD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI), and plaque index (PI) at 6 sites per tooth, except the third molars. The presence and type of the alveolar bone loss were assessed on the digital panoramic radiograph in each participant, which was supplemented with periapical radiographs if necessary. Periodontal status of each patient was evaluated by a single calibrated periodontists with a manual probe. The diagnosis of periodontitis or periodontal health was determined according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Periodontally healthy individuals (n=17) in the control group had no sites with PD >3 mm and CAL >2 mm and also no radiographic evidence of alveolar bone loss. BOP was <10%.
The periodontitis stage III patients had a minimum of three teeth apart from the first molars and incisors showing CAL ≥5 mm and PD ≥6 mm and showed no>4 teeth loss because of periodontitis. Radiographic bone loss extending from coronal to middle third or beyond. Radiographic bone loss was determined from the tooth showing the most severe bone loss as a percentage of root length. If the values of bone loss %/age were between 0.25 and 1.0, the patients were assigned to grade B (n=16). If higher than 1.0, the patients were assigned to grade C (n=16).
Treatment
Patients in the periodontitis groups underwent quadrant-wise supra and subgingival mechanical scaling and root planing using ultrasonic scalers and manual instruments, after administration of local anesthesia. No periodontal intervention was carried out in the periodontally healthy controls.
Saliva and Serum Sampling
A total of 5 mL of unstimulated whole saliva was collected by passive drool method between 9:00 and 10:00 am. The participants were advised to avoid food consumption for three hours before sample collection. The participants were seated upright, and saliva was collected over a period of 5 minutes with instructions to pool saliva in the floor of the mouth and passively drool it into a sterile glass beaker. Then saliva samples are immediately transferred to a 2 mL polypropylene tube and stored at -80°C. A total of 5 mL of blood was collected from the antecubital fossa by vene puncture method. Serum was isolated from the blood by centrifuging at 5000 rpm for 10 minutes followed by its rapid transfer to a sterile polypropylene tube and storage at -80°C.
Biomarker Immunoassays Saliva and serum samples were thawed on ice. The saliva samples were centrifuged at 5.000 rpm for 15 minutes at room temperature, and supernatants were immediately used for assays. Serum and salivary samples of SIRT-1 , MMP-9, MIP-1α*, T-SOD were measured by ELISA using commercial kits.
Statistical Analysis
All statistical analyses were carried out with the standard statistical software package. For the intra-group comparisons, if the data were not normally distributed, Wilcoxon-signed rank test and the Dunn test with the Bonferroni correction were used to analyze the change between baseline and 3 months after treatment. For inter-group comparisons, Mann-Whitney U test for normally and non-normally distributed data. The Spearman's rank correlation test was used to detect the correlations of biochemical parameters with clinical parameters and each other's in diseased group before and after treatment. All tests were performed at significance level of P <0.05.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Periodontally Healthy | No intervention | –Periodontally healthy patients received no intervention. |
| Periodontitis Stage III Grade B | Active comparator | Procedure: Non-surgical periodontal treatmentThe patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia by the use of ultrasonic scalers and curettes. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks. |
| Periodontitis Stage III Grade C | Active comparator | Procedure: Non-surgical periodontal treatmentThe patients were subjected to quadrant-wise full-mouth subgingival scaling and root planning under local anesthesia by the use of ultrasonic scalers and curettes. The entire non-surgical periodontal treatment of periodontitis groups was completed in a total of 4 sessions in two weeks. |
Who may qualify
- Ages
- 23 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- systemically healthy and non-smoker individuals
- having ≥20 teeth present (except third molars)
- individuals with periodontally healthy, periodontitis stage III grade B and C diagnoses
Key exclusion criteria (5 listed)
- having any diagnosed medical disorders such as diabetes mellitus, cardiovascular diseases, rheumatoid arthritis, immunological and mucocutaneous diseases
- usage of antibiotics, non-steroidal anti-inflammatory drugs and immunosuppressive agents within the past 6 months
- having any non-inflammatory destructive periodontal disease
- nonsurgical/surgical periodontal therapy received in the past year
- pregnant/ lactating/ postmenopausal females.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Non-surgical periodontal treatmentNon-surgical periodontal treatment involves the removal of microbial dental plaque and calculus by mechanical debridement using manual and ultrasonic instruments. Motivating and educating patients about oral hygiene procedures is another important part of the treatment. The aim is to stop the progression of the disease and to prevent the occurrence of active clinical inflammation. | Procedure or surgery | Periodontitis Stage III Grade B, Periodontitis Stage III Grade C |
Primary outcome
Salivary SIRT-1 (ng/mL) level
Time frame: baseline to 3 months after treatment
change in salivary SIRT-1 levels from baseline to 3 months after treatment
Salivary MMP-9 (ng/mL) level
Time frame: baseline to 3 months after treatment
change in salivary MMP-9 levels from baseline to 3 months after treatment
Salivary T-SOD (U/mL) level
Time frame: baseline to 3 months after treatment
change in salivary T-SOD levels from baseline to 3 months after treatment
3 secondary outcomes
Serum SIRT-1 (ng/mL) level
Time frame: baseline to 3 months after treatment
Serum MMP-9 (ng/mL) level
Time frame: baseline to 3 months after treatment
Serum T-SOD (U/mL) level
Time frame: baseline to 3 months after treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Feb 2024.
- Derived from this study: PubMed 39972299Iyigun S, Gorgulu NG, Dogan B. Changes in MMP-9, T-SOD and SIRT-1 levels after non-surgical periodontal treatment. BMC Oral Health. 2025 Feb 19;25(1):262. doi: 10.1186/s12903-025-05610-5.
Related trials for Periodontal Health
Not yet recruitingObservational study
Salivary and GCF Biomarkers in Periodontal Health, Gingivitis and Periodontitis
Periodontal Health, Gingivitis
Not yet recruiting
Education-Based Oral Health Promotion Intervention During Pregnancy: Implementation Protocol in Bangladesh
Pregnancy, Periodontal Diseases
RecruitingObservational study
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Diabete Mellitus, Dyslipidaemia
Active, not recruitingObservational study
Periodontal Health in Adults Treated With Fixed Orthodontic Appliances or Clear Aligners
Malocclusion, Periodontal Diseases
Active, not recruitingObservational study
Evaluation of the Effect of Smoking on Apelin, Periostin, and High-Sensitivity CRP Levels in Gingival Crevicular Fluid and Serum
Periodontitis (Stage 3), Periodontal Health
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Non-surgical periodontal treatment in people with Periodontal Health and Periodontitis, run by Marmara University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Salivary SIRT-1 (ng/mL) level (time frame: baseline to 3 months after treatment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06255470, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Feb 2024; AzTrials last refreshed its copy on 8 Nov 2026.